Complete resolution of generalized lichen planus after treatment with thalidomide.

Thalidomide has gained an infamous history due to severe birth defects observed in patients who had taken the drug to control nausea during pregnancy. The medication was withdrawn from the market because of its teratogenicity, but was approved by the FDA in 1998 for the treatment of erythema nodosum leprosum. However, thalidomide has been employed with success by dermatologists for a host of off-label uses including the treatment of lichen planus. Currently, no clinical trials or studies exist to evaluate the efficacy of using thalidomide to treat lichen planus, but case reports have been published in the medical literature supporting its therapeutic benefits. TNF-alpha is among the many cytokines that have been implicated in the pathogenicity of lichen planus. It is thought that thalidomide acts.
AuthorsJennifer L Maender, Ravi S Krishnan, Tiffany A Angel, Sylvia Hsu
JournalJournal of drugs in dermatology : JDD (J Drugs Dermatol) 2005 Jan-Feb Vol. 4 Issue 1 Pg. 86-8 ISSN: 1545-9616 [Print] United States
PMID15696990 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Immunosuppressive Agents
  • Thalidomide
  • Adult
  • Diabetes Complications (drug therapy)
  • Female
  • Hepatitis C (complications)
  • Humans
  • Immunosuppressive Agents (therapeutic use)
  • Lichen Planus (drug therapy, pathology)
  • Skin (pathology)
  • Thalidomide (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: